VOLITIONRX LTD

VNRX NYSE CIK: 0000093314

Company Information

Industry In Vitro & In Vivo Diagnostic Substances
SIC Code 2835
Entity Type operating
SEC Category Non-accelerated filerSmaller reporting company
State of Incorporation DE
Business Address 1489 WEST WARM SPRINGS ROAD, HENDERSON, NV, 89014
Mailing Address 1489 WEST WARM SPRINGS ROAD, HENDERSON, NV, 89014
Phone 1 (512) 774-8930
Fiscal Year End 1231
EIN 911949078

Financial Overview

FY2025 FY

$1.73M
Revenue
$9.40M
Total Assets
$42.49M
Total Liabilities

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events April 1, 2026 View on SEC
10-K Annual financial report March 31, 2026 View on SEC
8-K Current report of material events March 31, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
4 Insider stock transaction report March 19, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC
4 Insider stock transaction report March 3, 2026 View on SEC

Annual Reports

10-K March 31, 2026
  • Nu.Q® Vet cancer test is commercially available in over 20 countries.
  • Strategic licensing partnerships established with industry leaders like Werfen, Hologic, and IDEXX.
View Analysis

Material Events

8-K Financial Distress March 31, 2026
High Impact
  • Revenue growth of 40% YoY to $1.7 million, with Q4 revenue jumping 133%.
  • Operating expenses reduced by 17% to $19.7 million, narrowing annual losses.
View Analysis
8-K Financial Distress February 9, 2026
High Impact
  • VolitionRx develops novel blood-based diagnostic tests for serious diseases like cancer.
  • Its Nu.Q® platform technology shows promise.
View Analysis

Related Companies

Companies in the same industry (SIC: 2835)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.